Home โบ Glioma
Glioma clinical trials recruiting in the U.S.
118 studies for Glioma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY25 studies
- Houston, TX23 studies
- Washington, DC20 studies
- Boston, MA20 studies
- Philadelphia, PA16 studies
- Miami, FL15 studies
- Columbus, OH15 studies
- San Francisco, CA14 studies
- Chicago, IL13 studies
- Durham, NC12 studies
- Seattle, WA11 studies
- St. Louis, MO10 studies
- Aurora, CO10 studies
- Los Angeles, CA10 studies
- Cincinnati, OH9 studies
- Rochester, MN9 studies
- Edison, NJ8 studies
- Atlanta, GA7 studies
- Queens, NY7 studies
- Orange, CA6 studies
- Birmingham, AL6 studies
- San Diego, CA6 studies
- Dallas, TX6 studies
- Nashville, TN6 studies
- Omaha, NE6 studies
- Jacksonville, FL6 studies
- Baltimore, MD6 studies
- Ann Arbor, MI5 studies
- San Antonio, TX5 studies
- New Rochelle, NY5 studies
- Cleveland, OH5 studies
- Winston-Salem, NC4 studies
- Mountain View, CA4 studies
- Staten Island, NY4 studies
- East Norwalk, CT4 studies
- Greenburgh, NY4 studies
- Phoenix, AZ4 studies
- Tampa, FL4 studies
- Indianapolis, IN4 studies
- Detroit, MI4 studies
By state
- Alabama6 studies
- Arizona8 studies
- Arkansas3 studies
- California25 studies
- Colorado11 studies
- Connecticut5 studies
- District of Columbia14 studies
- Florida23 studies
- Georgia7 studies
- Illinois13 studies
- Indiana4 studies
- Iowa3 studies
- Maryland12 studies
- Massachusetts20 studies
- Michigan8 studies
- Minnesota13 studies
- Missouri11 studies
- Nebraska6 studies
- New Jersey10 studies
- New York28 studies
- North Carolina16 studies
- Ohio18 studies
- Pennsylvania19 studies
- Tennessee8 studies
- Texas26 studies
- Utah4 studies
- Virginia5 studies
- Washington11 studies
Recently updated studies
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 to 99 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07416188Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07326566A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RecruitingPhase 1/2
12 Months โ 21 Years ยท All sexes ยท Updated Sep 25, 2026 ยท NCT05099003MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT03896568A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
Up to age 25 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04094610Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RecruitingEarly phase 1
Ages 1 to 21 ยท All sexes ยท Updated Sep 22, 2026 ยท NCT05555550ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
RecruitingPhase 2
12 Months โ 39 Years ยท All sexes ยท Updated Sep 21, 2026 ยท NCT06838676Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 21, 2026 ยท NCT04977375Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Recruiting
Ages 15 to 120 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT07374692Development of MRF for Characterization of Brain Tumors After Radiotherapy
RecruitingHealthy volunteers welcome
Ages 18 to 60 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT06101069A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
RecruitingPhase 1
Ages 5 to 18 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT06357377Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT04771806A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT05698524MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT04373720NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
RecruitingPhase 1
Ages 3 to 25 ยท All sexes ยท Updated Sep 9, 2026 ยท NCT07664176Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
RecruitingPhase 1
36 Months ยท All sexes ยท Updated Sep 9, 2026 ยท NCT07076498Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
12 Months โ 39 Years ยท All sexes ยท Updated Sep 8, 2026 ยท NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months โ 22 Years ยท All sexes ยท Updated Sep 4, 2026 ยท NCT03911388A Study of Mirdametinib in People With Central Nervous System Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 3, 2026 ยท NCT07539441Assessing Brain Metabolism Using MRS With Deuterated Glucose
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT06594315Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
Ages 12 to 39 ยท All sexes ยท Updated Sep 1, 2026 ยท NCT06161974Glioma Developmental and HyperActive Ras Tumor (DHART) Board
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Aug 31, 2026 ยท NCT05489783SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT05303519A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RecruitingPhase 1/2
Ages 15 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT05588141PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RecruitingPhase 2
Ages 3 to 39 ยท All sexes ยท Updated Aug 24, 2026 ยท NCT05096481From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.